U.S. Court Backs U.S. FDA Over Wyeth's Plea To Protect Zosyn From Orchid's Generic Copies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a blow to Wyeth in its attempts to protect anti-bacterial combination injection Zosyn (piperacillin/tazobactum), the U.S. District Court of Columbia dismised a plea for a temporary restraining order against the U.S. FDA's decision to approve generic copies of the drug from India's Orchid Chemicals
You may also be interested in...
Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals
WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage
Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals
WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage
Wyeth To See First Copies Of Tazocin In EU From Orchid Chemicals
MUMBAI - U.S. drug maker Wyeth will see its first competition in Europe for key antibiotic drug Zosyn, or Tazocin, from Indian drug maker Orchid Chemicals. After almost a wait of more than a year, Orchid received approvals or Marketing Authorization for piperacillin/tazobactum injectibles in the EU countries